Changing Skin. Changing Lives.
See what real people have to say about their experiences with Obagi Nu-Derm.
The testimonials presented are based on these users’ experiences; and individual results may vary.
Watch Corinne’s video as she describes how Obagi Nu-Derm® helps her keep signs of aging at bay. Using the system helped Corinne reduce hyperpigmentation, uneven skin tone, and dark spots. With her skin tone and confidence back, it’s no wonder she was selected to be one of our 2013 Obagi Ambassadors.
See Important Safety Information about the Obagi Nu-Derm System below.
Hear what others are saying about Obagi Nu-Derm:
“We have used the Obagi Nu-Derm skin care system for 17 years, and I have not found any other system that is comparable to the excellent results for rejuvenating and maintaining healthy skin.”
Jody Comstock, MD
Skin Spectrum, Tucson, AZ
“I really didn’t like the texture of my skin, my pore size, and I had a lot of hyperpigmentation. I was a little intimidated to have to use so many products and have to buy into some sort of system. I was skeptical. But all I can say is WOW! What a transformation.”
“I started the Obagi [Nu-Derm] System about 2 weeks ago to improve melasma on my face after my dermatologist recommended that I try it.
“WOW! In only 2 weeks, most of my melasma has improved and the really tough spots I’ve had for years are noticeably faded!* I am so delighted with your product! Even the redness and peeling (which I was warned ahead of time would happen) were very manageable.
“Some women in my office approached me the other day to ask what I was doing to my skin because it looked so smooth and radiant. I was floored! Again, thank you.”
*Results may vary.
The safety and effectiveness of the Nu-Derm System beyond 24 weeks of use have not been established. If no improvement is seen after 3 months of treatment, use of this product should be discontinued.
Important Safety Information for Obagi Nu-Derm Clear, Blender® and Sunfader
(contains 4% hydroquinone)
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.
Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.
Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.
Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.